tbuckley/cabot-search huggingface dataset:
Magnesium sulfate and digitalis-toxic arrhythmias
Authors: John P. Sheehan
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The report of Cohen and Kitzes<sup>1</sup>and subsequent correspondence<sup>2</sup>attributed the occurrence of idionodal tachycardia to digoxin toxicity in the presence of mid-normal therapeutic levels of digoxin, rather than to an intrinsic arrhythmogenic effect of magnesium deficiency. In the face of an arrhythmia known to occur in otherwise healthy persons and patients with various forms of cardiac disease, not to mention the associations of magnesium deficiency with both ventricular and supraventricular tachyarrhythmias, I find it exceedingly difficult to attribute conclusively the arrhythmia to digoxin toxicity per se. I fully agree with the authors regarding the need for prompt correction of magnesium depletion with intramuscular (IM) or intravenous magnesium; however, I remain a little concerned about the author's dosage schedule and reliance on lymphocyte magnesium estimations as reliable markers of intracellular magnesium deficiency. Personal experience<sup>1</sup>in treating 21 severely hypomagnesemic patients (mean serum magnesium level, 1.08
Antidepressants and hypothalamic-pituitary-adrenocortical regulation
Authors: F. Holsboer
Journal: Endocrine Reviews (1996)

PAST studies of antidepressants have focused almost exclusively on their effects on the metabolism and receptors of monoamine neurotransmitters in various brain regions. These studies have been extended to the molecular effects of antidepressants and have led to a profoundly expanded understanding of their actions in the central nervous system. For example, long-term administration of antidepressants decreases the expression of tyrosine hydroxylase, down-regulates cAMP-dependent protein kinase, modulates the mRNA expression of central β-adrenoceptors and serotonin (5-HT) receptors, and alters the functional activity of specific G protein subunits and adenylyl cyclase (1). Taken together, these and many other recent observations clearly indicate that antidepressants interfere not only with the production and release of catecholamines and indolamines but also with the signal transduction of those neurotransmitters that have long been implicated in the pathogenesis and treatment of depression. More recently, additional target genes of antidepressant treatment have been identified, the most intriguing being those related to hypothalamic-pituitary-adrenocortical (HPA) activity. Altered regulation of this neuroendocrine system has been the subject of investigative efforts in depression research since Gibbons (2) reported more than 30 yr ago that plasma cortisol concentrations are elevated in depression and are normalized after clinical remission. Numerous clinical observations are consistent with the possibility that there is a causal link between HPA dysregulation and psychopathology (3). Recently, a large number of preclinical studies have provided evidence pointing in the same direction.
Abstract 3330: Circulating HPV DNA as a biomarker for metastatic cervical cancer detection, genotyping and monitoring
Authors: Zhigang Kang, Sanja Stevanović, Christian Hinrichs, Liang Cao
Journal: Cancer Research (2019)

Abstract Purpose: Circulating cell-free (cf) human papillomavirus (HPV) DNA is a unique tumor marker for metastatic cervical cancers. We developed a method to genotype and quantify blood circulating HPV DNA in patients with metastatic cervical cancer for patient selection, treatment monitoring, as well as informing data on an experimental T cell therapy. Patients and Methods: we developed a digital droplet (dd) PCR method for HPV genotyping and quantification with cfDNA. In a retrospective study, HPV cfDNA was measured in serum samples from nine metastatic cervical cancer patients received tumor-infiltrating lymphocyte (TIL) immunotherapy. cfDNA data were aligned with the tumor HPV data, drug treatment, and clinical outcome. In a HPV screening, the genotyping and DNA copy number of HPV cfDNA from 47 cervical cancer patients were measured and the allele frequencies were determined in relative to total genomic cfDNA of each patient. Results: The ddPCR assay is highly sensitive, specific, and capable of accurate quantification of both HPV16 and HPV18 cfDNA. In the clinical validation, we detected HPV cfDNA from 19/19 (100%) patients with HPV-positive metastatic and recurrent cervical cancer but not in any of the 45 healthy blood donors. The HPV genotype harbored in the patients’ tumors was correctly identified in 87/87 (100%) sequential patient serum samples. Our data showed the use of HPV cfDNA for pharmacokinetic studies, effectiveness on an investigational therapy, and patient monitoring. In three patients who experienced objective responses, a transient HPV cfDNA peak was detected 2-3 days after TIL immunotherapy and a persistent clearance of HPV cfDNA was observed in only two patients with a complete response (CR). Among the HPV positive cases, the median HPV cfDNA allele frequency is above 30% of genomic single copy genes in these cervical cancer patients. Conclusions: We developed and validated a highly sensitive and specific HPV cfDNA genotyping and quantification method. As a promising non-invasive tumor marker, HPV cfDNA may have value in detecting the efficacy of therapeutic agents and monitoring cervical cancer patients in remission. The cfDNA based HPV genotyping is currently being evaluated for patient selection in an experimental T-cell therapy against a specific HPV antigen. HPV cfDNA may also be a potential biomarker for early diagnosis of cervical cancer. Citation Format: Zhigang Kang, Sanja Stevanović, Christian Hinrichs, Liang Cao. Circulating HPV DNA as a biomarker for metastatic cervical cancer detection, genotyping and monitoring [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3330.
Cancer
Authors: Randall Hughes
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Netlines
Authors: M. Pallen
Journal: BMJ (1997)

Note: The BMJ can't guarantee the currency or continued maintenance of URLs or web sites (aside from its own) that appear in Netlines. If a link to a third-party site fails, please consult your favorite search engine. If a BMJ link fails, please send us feedback web pagehttp://www.qmw.ac.uk/~rhbm001/mpallen.html
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.
Authors: G. Zalcman, J. Margery, A. Scherpereel, P. Astoul, I. Monnet, B. J. Milleron, L. M. Paule, M. André, D. Moro-Sibilot, J. Mazieres
Journal: Journal of Clinical Oncology (2010)

7020 Background: MPM median OS does not exceed 13 months with pem/CDDP doublet. U.S. Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab, gave an appealing 15.6 months median OS in the bevacizumab arm. French Intergroup aimed to test pem/CDDP with bevacizumab (PCB), in a randomized phase II-III trial. Methods: Eligible patients had unresectable histologically proved MPM, no prior chemo, PS 0-2, no thrombosis, nor bleeding. Primary endpoint: % of nonprogressive patients at 6 months. Statistics: H0: p ≤ 40% vs. H1: P ≥ 60%; binomial exact test: 50 assessable patients in each arm, and 25 nonprogressive patients in the bevacizumab arm to begin the phase III (94.3% Power, α=9.8%). Patients received pem 500 mg/m2, CDDP 75 mg/m2 (PC),at D1, with (arm B) or without bevacizumab (arm A), 15 mg/kg Q21D, for 6 cycles. Arm B non- rogressive patients received bevacizumab maintenance therapy until progression or toxicity. Enrollment was achieved within 24 months in 53 French centers. Results: On January 7, 2010, 111 patients were enrolled. Med.age: 64.3 (34.7-75.5), M:F = 80:31, epithelioid:sarcomatoid/mixt = 90:21, WHO PS 0:1:2 = 49:57:5. In the 72 first patients reaching 6 months evaluation, 455 cycles of chemotherapy have been analyzed. 11/72 patients (15.3%) had grade 4 events related to chemotherapy. There was no significant difference in grade 3/4 toxicity between the two arms. AE are presented in the Table (max. toxicity for each patient). In the first 71 assessable patients (1 noneligible), there were 25/34 patients (73.5%) with DC (1 CR, 15 PR, 9 stable disease) in Arm B vs. 16/37 (43.2%) in arm A (p=0.010). Conclusions: PCB chemo was well-tolerated and feasible. The statistical endpoint of the phase II study has been reached. Updated toxicity data, PFS, and DCR at 6 months will be presented at the Meeting. Arm A % Arm B % Grade 3 % Grade 4 Grade 3 % Grade 4 n = 37 n = 37 n = 35 n = 35 Anorexia 3 8.1% 0 0 0 Asthenia 6 16.2% 0 5 14.3% 0 Pulmonary embolism 0 0 0 2.8% 3 8.6% Hypertension 0 0 3 8.6% 0 Neutropenia 14 37.8% 3 8.1% 12 34.3% 4 11.4% Febrile neutropenia 1 2.7% 0 0 2.8% 0 Thrombopenia 0 10.8% 0 2.7% 0 2.8% 0 Vomiting 0 5.4% 0 0 5.6% 0 2.8% Creatinine increase 0 0 3 8.6% 0 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca, GlaxoSmithKline, Lilly, Roche AstraZeneca, GlaxoSmithKline, Lilly, Merck Serono, MSD France, Roche Lilly, Roche Lilly, Roche
Hemodialysis-associated hepatitis. An outbreak among hospital personnel
Authors: C. H. Hennekens
Journal: JAMA (1973)

During an 11-month period, 11 cases of viral hepatitis were recognized in personnel of a hospital in Miami Beach, Fla. Epidemiologic evidence suggested that a single hemodialysis patient, an asymptomatic carrier of hepatitis B antigen, was the source of hepatitis virus for ten of the 11 cases.
Public Health Assessment—Russian Federation
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GASTRIC DISTURBANCES
Authors: A. J. BEAMS
Journal: JAMA (1930)

<h3>ROUTINE 3</h3><h3>FOODS ALLOWED</h3><h3>Beverages:</h3> Buttermilk, cocoa, weak coffee, eggnog, malted milk, milk, milk and cream, postum, S. M. A., tea, Kaffee Hag. <h3>Cream Soups:</h3> Made with sweet cream, sour cream or white sauce and strained vegetables; oyster stew, clam broth and chicken broth. <h3>Breads:</h3> Any except very fresh breads. <h3>Eggs:</h3> Any style except fried. <h3>Fats:</h3> Butter, cream, oil and oleomargarine. <h3>Cereals:</h3> Bran flakes, cornflakes, cornmeal, cream of wheat, farina, hominy, malt breakfast food, strained oatmeal, pettijohns, puffed rice, puffed wheat, ralstons, rice, shredded wheat biscuit. <h3>Desserts:</h3> Apple snow, custard, gelatin, junket, prune whip, rice and other simple puddings, tapioca; ice cream, ices, sponge cake or simple cup cakes. <h3>Fruits:</h3> Cooked—apples, apricots, white cherries, peaches, pears, red raspberries, strawberries; dried and stewed—apricots, figs, prunes; fresh—apricots, figs, peaches, pears, red raspberries, strawberries (grapefruit, oranges, by permission of physician); juices—cherry, loganberry, orange, pineapple and strawberry (small amount of lemon juice). <h3>Vegetables:</h3> Cooked—asparagus,
PROGRESS IN THE STUDY OF MEASLES
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AUTHORS' REPLY
Authors: A. Morgan, N. Douglas
Journal: Thorax (1989)

We have read with interest the comments of Drs Gianotti and Franconieri.Their observation of a difference in expiratory time during sleep between subjects with intrinsic and extrinsic asthma is interesting but difficult to evaluate.Specifically, it is not clear whether there is a difference in the extent of nocturnal bronchoconstriction between their subjects with intrinsic and extrinsic asthma.As wheeze tends to be associated with prolonged expiration, one would imagine that the longer expiratory time in the patients with intrinsic asthma might have been associated with nocturnal bronchoconstriction.Paragraph 2, however, suggests that the patients with allergic asthma had nocturnal bronchoconstriction but those with intrinsic asthma did not.This requires clarification.Our own data are not directly comparable with the data of Drs Gianotti and Franconieri, as we did not split our patients into those with intrinsic and extrinsic asthma.Indeed, most had intrinsic asthma.We believe that our study adequately shows that there are no changes in breathing pattern overnight which are diagnos- tic of the development of nocturnal bronchoconstriction.We look forward to reading further details of the study of Drs Gianotti and Franconieri in due course.
Abstract 1066: Drug resistant PDX models for testing targeted drug sensitivity
Authors: Jijun Cheng, Feifei Zhang, Zhen Zhou, Yuan Long, Wenhua Xu, Shizhu Zhao, Hongkui Chen, Shun Lu, Danyi Wen
Journal: Cancer Research (2019)

Abstract Advanced lung cancer of late stage patients is selectively sensitive to available targeted therapeutics and often develops resistance to early sensitive drug treatment, thus, the patient-derived xenograft (PDX) models are critical to evaluate drug sensitivity and resistance. We established PDX models from routine surgery tissues, as well as from tumor cells in pleural effusion specimens and from biopsies of advanced cancer patients who are refractory to treatments. Genetic profiling of the PDX lung models revealed a group of them with TKI drug-associated EGFR mutations (L858R, T790M, Exon19del, C797S). Among them, are an AZD9291-resistant sub-group with EGFR double mutations (Exon19Δ, T790M) in the clinic before AZD9291 treatment, and yet, acquired resistance to AZD9291 either through emergence C797S mutation or T790M loss in EGFR or through mutations in other pathways, providing insights into potential combo therapies. Indeed, combinations of AZD9291 with Cetuximab as well as with inhibitors targeting other signaling pathways such as MEK, are efficacious against an AZD9291-resistant lung PDX model with EGFR triple mutations (Exon19Δ, T790M, C797S). We also establish valuable lung models resistant to ALK inhibitors, Avastin, PD-1 antibody drugs, and resistant hematopoietic models. In summary, functional drug sensitivity profiling and genetic profiling with drug resistant PDX models provide insights into resistance mechanisms as well as precise therapeutic options against resistance emergence. Citation Format: Jijun Cheng, Feifei Zhang, Zhen Zhou, Yuan Long, Wenhua Xu, Shizhu Zhao, Hongkui Chen, Shun Lu, Danyi Wen. Drug resistant PDX models for testing targeted drug sensitivity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1066.
A patient's story: "My life revolves around food and exercise"
Journal: BMJ (2003)

Bulimia nervosa is an eating disorder that affects women 9-10 times more often than men.It has three key features:x Intense preoccupation with body weight and shape x Repetitive episodes of binge eating (uncontrollably eating a large quantity of food in a defined period-usually less than two hours)x Routinely taking extreme measures to prevent weight gain, including self induced vomiting, fasting, excessive exercise, and misuse of laxatives and diuretics.The condition is characterised by the patient's inability to control the urge to indulge in binge eating.Medical complications are caused by the weight reducing behaviours, particularly vomiting and laxative misuse.The frequency of these behaviours is, on average, at least twice a week for three months.Episodes may be spontaneous or planned and can be triggered by stress, intense hunger, or dysphoria.Patients are usually in the normal weight range. TreatmentDespite the availability of effective treatments, few people with bulimia nervosa seek help.One study found that only 1 in 10 people with the condition are in treatment. 1 Treatments that are likely to workAntidepressants Antidepressants can reduce binge eating and purging, and improve depressive symptoms and attitude towards food.There is not enough evidence on how long the benefits last or for comparing the effects of different classes of antidepressants.Antidepressants and cognitive behaviour therapy are equally effective for bulimia nervosa, though dropout rates are higher with antidepressants, probably due to their side effects.For information on drug doses, see www.besttreatments.org/bulimianervosa. Cognitive behaviour therapyAs with antidepressants, cognitive behaviour therapy can reduce binge eating and purging, and improve depressive symptoms and attitude towards food.It may be preferable to medication in patients who are sensitive to, or wish to avoid, side effects of medication.Cognitive behaviour therapy and other psychological treatments seem to be equally good at treating binge eating, although cognitive behaviour therapy is better at improving depression scores.There is some evidence that cognitive behaviour therapy has long term benefits in treating bulimia, but there is insufficient evidence about patients' characteristics that predict response.
CHIR258, a Novel Multi-Targeted Tyrosine Kinase Inhibitor, for the Treatment of t(4;14) Multiple Myeloma.
Authors: Suzanne Trudel, Zhi Hua Li, Ellen Wei, Marion Wiesmann, Katherine Rendahl, Eddie Moler, Chris Chen, Donna Reece, Joesph Mikhael, Carla Heise, A. Keith Stewart
Journal: Blood (2004)
Health officials investigate possible cause of dialysis encephalopathy
Authors: P. Gunby
Journal: JAMA (1979)

Aluminum toxicity is a prime suspect in dialysis encephalopathy, a frequently fatal complication of long-term hemodialysis that first was recognized in 1972. Recently the problem became the subject of a government epidemiologic investigation. Patients in whom this problem develops experience increasingly severe neurological and motor difficulties. There may be seizures that do not respond to anticonvulsant drugs. Motor control degenerates until the patients become immobile. Speech grows hesitant, then is complicated by stuttering, inability to think of the desired word, and problems in structuring sentences, finally resulting in a total inability to talk. This condition also is known as dialysis dementia because patients often deteriorate intellectually, become depressed or paranoid, hallucinate, or have other psychoses. The diagnosis usually is made on the basis of these clinical findings. Because of the variety of problems that may develop, and because exposure to aluminum has not been proved to be the cause, investigators
Abstract 168: Evaluation Of Coronary Arterial Sequelae Due To Kawasaki Disease Using Optical Coherence Tomography
Authors: Nobuyuki Kakimoto, Hiroyuki Suzuki, Takashi Kubo, Tomohiro Suenaga, Takashi Takeuchi, Shoichi Shibuta, Yasushi Ino, Takashi Akasaka, Norishige Yoshikawa
Journal: Circulation (2015)

Objectives: Optical coherence tomography (OCT) is an intracoronary arterial imaging modality employing near-infrared light to create images. OCT makes it possible to distinguish the three layers of the coronary arterial wall. However, few previous studies have used OCT to evaluate coronary arterial lesions (CAL) in Kawasaki disease (KD). Here we report the use of OCT to evaluate CALs in KD. Patients and Methods: Fifteen patients aged between 11 and 29 years were admitted to undergo coronary angiography (CAG) for follow-up of KD. The male : female ratio was 11:4. Their ages at disease onset and when OCT was performed were 1m - 10y11m (median; 1y2m), and 11y1m - 29y3m (median; 16y2m), respectively. The interval between disease onset and OCT examination was 5y1m - 24y4m (median; 13y2m). Repeated CAG was performed on the basis of the criteria stipulated in the guidelines for cardiovascular sequelae in KD (JCS 2008). At the time of the latest CAG, we performed not only regular CAG but also IVUS and OCT (C7 OCT imaging system, St Jude Medical, St. Paul, MN, USA) for coronary arteries between December 2012 and August 2014. Results: We demonstrated fresh thrombus, stenosis, fibrotic intimal thickening with lamellar calcification and partial disappearance of the tunica media in CAL. Fibrotic intimal thickening and disruption of the tunica media are demonstrated in all patients. In addition, OCT demonstrated intimal thickening and disruption of the tunica media in completely regressed lesions and even in regions where CAG had shown normal coronary arterial walls in the acute phase. Conclusions: Our data suggest that fibrotic intimal thickening and disruption of the tunica media may be basic changes of coronary arterial sequelae in KD. The use of OCT for evaluation of KD vasculitis may clarify the mechanisms responsible for coronary arterial sequelae and be useful for prognostication of CAL.